<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/09/New-Project70-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/09/New-Project70-430x241.jpg"/>
                                    
                                    <figcaption>Sobi holds exclusive rights to market Tryngolza outside the US, Canada and China. Credit: Swedish Orphan Biovitrum AB. </figcaption>
                                </figure>
                            </div>
                                             
     
<p>Ionis Pharmaceuticals and Sobi have announced the approval of Tryngolza (olezarsen) in the European Union (EU) for adults with familial chylomicronemia syndrome (FCS).</p>



<p>FCS is a rare genetic condition that leads to extremely high triglyceride levels, often exceeding 880 mg/dL, compared to normal levels below 150 mg/dL. </p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports</div><h4>LOA and PTSR Model - AROAPOC-3 in Familial Chylomicronemia (Type I ... </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports</div><h4>LOA and PTSR Model - AROAPOC-3 in Hypertriglyceridemia </h4></div> </li></ul> <div>
                    <h5>
                        
                            
                        
                        Data Insights
                    </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>Tryngolza is a ribonucleic acid (RNA)-targeted therapy designed to reduce the production of apoC-III, a protein involved in triglyceride metabolism. </p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>It is already approved in the US and is also under evaluation for severe hypertriglyceridemia (sHTG), characterised by fasting triglyceride levels of 500mg/dL or higher. </p>



<p>The EU approval follows a favourable recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). </p>



<p>Ionis CEO Brett Monia stated: “The EU approval of Tryngolza is a significant advance for the treatment of FCS. </p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>“Tryngolza has the potential to be a transformative treatment option for FCS patients in the EU who are at risk of debilitating and life-threatening acute pancreatitis attacks. </p>



<p>“We are proud to work with Sobi, a long-standing partner of Ionis and the FCS community, to make Tryngolza available to people with FCS in the EU.” </p><div id="slot-two"></div>



<p>The EU approval is supported by data from the Phase III Balance trial, which evaluated the efficacy and safety of olezarsen in FCS patients.  </p>



<p>The therapy showed significant reductions in fasting triglyceride levels at six months and maintained them over a year. </p>



<p>It also showed a significant decrease in acute pancreatitis incidents. </p>



<p>Results from the study, published in <em>The New England Journal of Medicine,</em> indicated a favourable tolerability and safety profile for Tryngolza. </p>



<p>In March 2025, Ionis and Sobi entered a licence agreement for the commercialisation of Tryngolza. </p>



<p>Sobi holds exclusive rights to market the drug outside the US, Canada and China. </p>
<div id="slot-three"></div><p></p>



<div>
    
</div>



                   
               <div>
                 <h2>Pharmaceutical Technology Excellence Awards - The Benefits of Entering</h2>
                 <p>Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!</p>
Nominate Now

             </div>

IONS

<p>Ionis Pharmaceuticals and Sobi have received EU approval for Tryngolza (olezarsen) to treat adults with familial chylomicronemia syndrome (FCS), a rare genetic disorder causing high triglyceride levels. Sobi will market the drug outside the US, Canada, and China. The approval follows a positive recommendation from the European Medicines Agency and is based on Phase III trial data showing significant reductions in triglyceride levels and acute pancreatitis incidents. Ionis CEO Brett Monia highlighted the treatment's potential to transform care for FCS patients in the EU.</p>

Ionis and Sobi’s Tryngolza gains approval in EU for FCS treatment